INSM
NASDAQ · Biotechnology
Insmed Inc
$101.35
-3.65 (-3.48%)
Performance
1D
—
1W
—
1M
—
3M
-32.23%
6M
-47.19%
1Y
+55.73%
YTD
-42.78%
Open$108.01
Previous Close$105.00
Day High$108.63
Day Low$98.98
52W High$212.75
52W Low$63.81
Volume—
Avg Volume1.73M
Market Cap29.13B
P/E Ratio—
EPS$-6.40
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$168.11
Below
SMA 200
$139.54
Below
RSI (14)
54.8
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
26 analysts
Price Target
+41.5% upside
Current
$101.35
$101.35
Target
$143.40
$143.40
$91.17
$143.40 avg
$177.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 656.75M | 485.76M | 44.36B |
| Net Income | -1,382,750,556 | -920,470,044 | 1.08B |
| Profit Margin | -210.5% | -200.0% | 2.4% |
| EBITDA | -1,345,743,577 | -945,603,844 | 2.00B |
| Free Cash Flow | — | — | 843.11M |
| Rev Growth | +35.2% | +35.2% | +19.4% |
| Debt/Equity | 0.99 | 0.99 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |